Call customer care on: 0333 358 0200
meds prescribed online, delivered discretely to your door

Psoriasis meds prescribed online, delivered discretely to your door

We will recommend a personalised treatment plan for you

Enstilar Cutaneous Foam

Cream medication

A combination of foam spray containing betamethasone and calcipotriol used in the treatment and management of psoriasis vulgaris in adults.

Medication effect duration

Like any other prescription medication you must consult a doctor before using it. PrivateDoc offers a confidential free consultation service that may result in you receiving a prescription for Enstilar Cutaneous Foam if it is deemed appropriate and Enstilar Cutaneous Foam can be prescribed safely.

Skin treatment

Complete a 100% free and secure consultation to explore your treatment options. How our online prescription consultation works.

Ingredients

Each 1 gram of foam includes –

Calcipotriol monohydrate 50micrograms

Betamethasone dipropionate 0.5mg

A full list of non-active ingredients (excipients) can be found by clicking here to access the patient information leaflet.

What conditions can Enstilar Cutaneous Foam be used for

Enstilar Cutaneous Foam is licensed as a topical treatment for psoriasis vulgaris in adults.

Get Started

How to use Enstilar Cutaneous Foam

Enstilar Cutaneous Foam should be used exactly as your prescriber has instructed. The calcipotriol helps to reduce the rate at which your skin cells reproduce, and the betamethasone reduces the redness/inflammation.

The usual recommend dose is applying the foam once daily to the affected area(s) only. Treatment length is usually 4 weeks.

Maximum daily application should not exceed 15g – this corresponds to applicator being fully pressed for one minute. Pressing the applicator for 2 seconds will deliver approximately 0.5g of foam which should be enough to cover an area equal to the skin surface area of an adult hand.

If you are using other topical preparations which also include calcipotriol, then the over daily maximum should not exceed 15g. Enstilar Cutaneous Foam should not be used on more than 30% of the body surface area.

The can should be shaken for a few seconds before each application and sprayed onto the affected skin at a distance of 3cm. The cannister can be held in any orientation, except horizontally. Once sprayed onto the skin, Enstilar should be rubbed into the affected skin gently.

For the scalp, application should be onto the hands and then applied using the fingertips to the affected area(s). Hands should be washed immediately to prevent application to other parts of the body. Once applied, you should not have a bath or shower afterwards, instead the foam should be allowed to other either overnight or throughout the day.

Full instructions can be found in the product literature by clicking here.

Who cannot use Enstilar Cutaneous Foam

Enstilar Cutaneous Foam should not be used by anyone who has had a hypersensitivity reaction to either the active ingredients or any of the excipients. It is licensed for psoriasis vulgaris only and should not be used to treat erythrodermic or pustular psoriasis.

Enstilar should be avoided in any patient with a known calcium metabolism disorder. The corticosteroid content means it should be avoided in patients that have a rash caused by a virus (chickenpox, shingles, cold sores, etc.). Enstilar should also be avoided in patients where there is a likelihood of a fungal/bacterial infection or where the skin is broken.

A full list of contraindications and cautions is available by clicking here to access the full summary of product characteristics.

Get Started

Pregnancy and breastfeeding

There is no adequate data for use during pregnancy. Studies in animals with glucocorticoids have shown a level of toxicity but the impact of this in humans is uncertain. Therefore, Enstilar should only be used in pregnant females is the benefits of therapy outweigh the potential risks to the unborn foetus.

Betamethasone can pass into the breast milk but at therapeutic doses is not known to be harmful. There is no data on the excretion of calcipotriol in breast milk. Enstilar should be prescribed with caution to breastfeeding mothers. The cutaneous foam should not be used on the breasts if the mother is breastfeeding.

Side effects

Enstilar is generally well tolerated, but as is the case with all medication, a minority of patients may experience side effects from using the drug.

Side effects can include –

  • Hypersensitivity reactions
  • Blurred vision
  • Skin hypopigmentation
  • Skin atrophy
  • Hypercalcaemia
  • Rebound effects

A more complete list of side effects can be found in the patient information leaflet.

Get Started

Useful links

Click here for the Enstilar Cutaneous Foam patient information leaflet

Click here for the Enstilar Cutaneous Foam summary of product characteristics

Click here for the NHS psoriasis web link.